NextCure Price Target Maintained With a $4.00/Share by Needham
Piper Sandler Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $3
Buy Rating for NextCure Supported by Promising Clinical Results and Strong Financial Position
Needham Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $4
NextCure Analyst Ratings
NextCure Analyst Ratings
NextCure Analyst Ratings
Promising Clinical Outlook for NextCure's Novel ADC LNCB74 Spurs Buy Rating
NextCure Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)
Needham Maintains Buy on NextCure, Lowers Price Target to $4
NextCure Analyst Ratings
NextCure (NXTC) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Repare Therapeutics (RPTX), Cigna (CI) and NextCure (NXTC)
NextCure (NXTC) Initiated With a Buy at H.C. Wainwright
HC Wainwright & Co. Initiates Coverage On NextCure With Buy Rating, Announces Price Target of $7
NextCure Analyst Ratings
Piper Sandler Remains a Buy on NextCure (NXTC)
Needham Reiterates Buy on NextCure, Maintains $6 Price Target
NextCure Analyst Ratings
No Data